Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada

Background Combination antiretroviral therapy (ART) has significantly increased survival among HIV-positive adults in the United States (U.S.) and Canada, but gains in life expectancy for this region have not been well characterized. We aim to estimate temporal changes in life expectancy among HIV-positive adults on ART from 2000–2007 in the U.S. and Canada. Methods Participants were from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), aged ≥20 years and on ART. Mortality rates were calculated using participants' person-time from January 1, 2000 or ART initiation until death, loss to follow-up, or administrative censoring December 31, 2007. Life expectancy at age 20, defined as the average number of additional years that a person of a specific age will live, provided the current age-specific mortality rates remain constant, was estimated using abridged life tables. Results The crude mortality rate was 19.8/1,000 person-years, among 22,937 individuals contributing 82,022 person-years and 1,622 deaths. Life expectancy increased from 36.1 [standard error (SE) 0.5] to 51.4 [SE 0.5] years from 2000–2002 to 2006–2007. Men and women had comparable life expectancies in all periods except the last (2006–2007). Life expectancy was lower for individuals with a history of injection drug use, non-whites, and in patients with baseline CD4 counts <350 cells/mm3. Conclusions A 20-year-old HIV-positive adult on ART in the U.S. or Canada is expected to live into their early 70 s, a life expectancy approaching that of the general population. Differences by sex, race, HIV transmission risk group, and CD4 count remain.

[1]  Till Bärnighausen,et al.  Increases in Adult Life Expectancy in Rural South Africa: Valuing the Scale-Up of HIV Treatment , 2013, Science.

[2]  A. Phillips,et al.  Life expectancy living with HIV: recent estimates and future implications , 2013, Current opinion in infectious diseases.

[3]  Mardge H. Cohen,et al.  Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. , 2013, American journal of epidemiology.

[4]  A. Jemal,et al.  The influence of sex, race/ethnicity, and educational attainment on human immunodeficiency virus death rates among adults, 1993-2007. , 2012, Archives of internal medicine.

[5]  Richard D Moore,et al.  U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected Persons, 2000 to 2008 , 2012, Annals of Internal Medicine.

[6]  Michael Rayment,et al.  Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.

[7]  Huldrych F. Günthard,et al.  Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. , 2012, JAMA.

[8]  Jiaquan Xu,et al.  Deaths: final data for 2008. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[9]  J. Chmiel,et al.  Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment , 2011, AIDS.

[10]  N. Ford,et al.  Life Expectancy of Persons Receiving Combination Antiretroviral Therapy in Low-Income Countries: A Cohort Analysis From Uganda , 2011, Annals of Internal Medicine.

[11]  S. Deeks,et al.  HIV infection, inflammation, immunosenescence, and aging. , 2011, Annual review of medicine.

[12]  Evan Wood,et al.  Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study , 2010, The Lancet.

[13]  D. Shepard,et al.  Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward , 2010, The Lancet.

[14]  Marcie S Rubin,et al.  Examination of inequalities in HIV/AIDS mortality in the United States from a fundamental cause perspective. , 2010, American journal of public health.

[15]  A. Justice.  HIV and Aging: Time for a New Paradigm , 2010, Current HIV/AIDS reports.

[16]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[17]  Richard D Moore,et al.  Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  M. Boyd.  Improvements in antiretroviral therapy outcomes over calendar time , 2009, Current opinion in HIV and AIDS.

[19]  Evan Wood,et al.  Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study , 2009, BMJ : British Medical Journal.

[20]  B. Yip,et al.  The Combined Effect of Modern Highly Active Antiretroviral Therapy Regimens and Adherence on Mortality Over Time , 2009, Journal of acquired immune deficiency syndromes.

[21]  Ross J. Harris,et al.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2008, The Lancet.

[22]  P. Sullivan,et al.  Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. , 2008, Annals of internal medicine.

[23]  Douglas D. Richman,et al.  Antiretroviral Treatment of Adult HIV Infection , 2008 .

[24]  Richard D Moore,et al.  Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). , 2007, International journal of epidemiology.

[25]  Evan Wood,et al.  Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy , 2007, AIDS.

[26]  Evan Wood,et al.  Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia , 2006, AIDS.

[27]  Mark S Roberts,et al.  Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.

[28]  J. Robins,et al.  Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests , 2000, Biometrics.

[29]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[30]  M. Szyszkowicz,et al.  Life expectancy , 2019, OECD Pensions at a Glance.

[31]  C. L. Chiang,et al.  Introduction to stochastic processes in biostatistics. , 1968 .

[32]  D. Schadendorf,et al.  Increases in Adult Life Expectancy in Rural South Africa : Valuing the Scale-Up of HIV Treatment , 2022 .

[33]  T. Gross,et al.  For Personal Use. Only Reproduce with Permission from Elsevier Ltd Public Health Inequalities in Health between and within Countries: Poverty and Inequality Social Determinants of Health Inequalities , 2022 .